Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155508 | 0.87 | EGFR (0.44) | EGFRBTKDYRK1ARETMEN1 | |
| SCHEMBL24155873 | 0.87 | RET (0.50) | NAMPTEGFRBTKDYRK1ARET | |
| SCHEMBL24155858 | 0.86 | DYRK1A (0.46) | EGFRBTKDYRK1ARETMEN1 | |
| SCHEMBL24155658 | 0.85 | DYRK1A (0.45) | NAMPTEGFRBTKDYRK1AMEN1 | |
| SCHEMBL24155510 | 0.83 | MEN1 (0.58) | DYRK1ARETMEN1HTTKMT2A | |
| SCHEMBL31674515 | 0.83 | MEN1 (0.49) | EGFRBTKDYRK1ARETCYP1A2 | |
| SCHEMBL24155659 | 0.83 | MEN1 (0.49) | EGFRBTKDYRK1ARETCYP1A2 | |
| SCHEMBL21995639 | 0.82 | MEN1 (0.52) | DYRK1ARETMEN1KMT2ATGFBR1 | |
| SCHEMBL24155663 | 0.79 | TGFBR1 (0.50) | DYRK1ACYP1A2METAP2MEN1HTT | |
| SCHEMBL24155684 | 0.79 | DYRK1A (0.51) | DYRK1ARETMEN1KMT2ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403456-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY | SLC6A11, SCN1A, SCN1B | NAMPT 425/4885EGFR 4648/4885BTK 3398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.